Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH-006 in Untreated Chronic Hepatitis B Virus Infected Individuals
NCT07515209Phase 1Completed
- Sponsor
- Huahui Health
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic hepatitis B virus infection (CHB) comparing HH-006 with Placebo (2 arms). Primary endpoints: Incidence of adverse events and serious adverse events up to 24 weeks and Clinically significant abnormalities up to 24 weeks. Started Dec 2024; status: completed.
02
Drugs
HH-006
03
Conditions
chronic hepatitis B virus infection (CHB)
Beyond the preview
Go deeper on NCT07515209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07515209.